There's a billionaire fight happening in an Oakland federal courtroom right now. The headlines are calling it Elon Musk versus Sam Altman—tech titans, AI drama, billions at stake. But here's what almost nobody is telling you: if Elon wins this case, the next phone call won't be from Silicon Valley. It'll be from the general counsel's office at every nonprofit hospital in America.

The question on trial isn't really about AI chatbots. It's whether a charity that took tax-deductible donations under the explicit promise of serving the public can quietly convert itself into a for-profit empire where insiders pocket the upside. That is the exact business model of the modern nonprofit hospital.

In this episode, I break down the numbers nobody talks about, the smoking gun study from Health Affairs, the three legal doctrines on trial, and what happens next—whether Musk wins, loses, or lands somewhere in between.

Watch on YouTube: https://youtu.be/gXCwinAwrMA

Read the full breakdown: https://open.substack.com/pub/danmccoymd/p/is-your-local-hospital-doing-exactly

A 6-month-old named KJ Muldoon just received the first personalized CRISPR gene therapy ever made — designed, manufactured, and administered for his exact mutation in six months. Nature named him to the Top 10 People Who Shaped Science of 2025.

The miracle is real. The financing model isn't.

Gene therapies run $2M to $3.5M each. Insurance contracts are annual. Gene therapy benefits last a lifetime. The employer who pays in year one rarely sees the savings — average commercial plan tenure is three years.

In this episode:

— Why the "gene therapy tsunami" narrative is overstated (EBRI's numbers tell a different story)

— The free-rider problem and why annual contracts can't price lifetime cures

— The concierge medicine paradox: we pay $3M to cure you, but won't pay $300/mo to keep you healthy

— Four financing models worth knowing for 2026: gene-therapy-specific stop-loss, outcomes-based agreements, risk-pooling platforms, and performance-based annuities

— How AI is compressing drug development timelines — and why that compounds the budget problem

We have 21st century cures and 20th century accounting. Eventually, one of those has to change.

Watch the full video: https://youtu.be/ap2XjNf3LN0

Read the Substack companion piece: https://open.substack.com/pub/danmccoymd/p/21st-century-cures-20th-century-accounting

Full sources and the deep dive: danmccoymd.substack.com

If you're a medical student picking a specialty in 2026, you're being asked to bet a decade and $300,000 in debt on a market nobody is teaching you to read.

This episode is the framework I wish someone had given me — plus the data nobody else is putting in front of med students.

In this episode:

• Why 76% of all FDA-cleared medical AI targets a single specialty — and why residency applications to it are still up 30%
• The four kinds of physician cognition (and why "AI replaces cognitive work" is the wrong frame entirely)
• Which specialties get repriced, restructured, or protected — and why psychiatry might be safer than radiology
• The 2026 CMS efficiency adjustment nobody is talking about — and why it's a ratchet, not a one-time cut
• What medical schools are (and aren't) doing to prepare the next generation of physicians for an AI-driven workforce

Watch the video version with charts and visuals: https://youtu.be/NETog9SBtZs

Full sources and the deep dive: danmccoymd.substack.com

Last week the Texas Medical Association joined a federal antitrust lawsuit against MultiPlan — recently rebranded as Claritev. The story being told is doctors versus insurers, an unlawful cartel, $19B in alleged underpayments. It's a clean story. The moment you look at the actual fee math from the complaint, it falls apart.

In this episode I walk through MDL 3121, the $1,000 → $200 cascade, the DOJ's March 27 Statement of Interest backing the plaintiffs' antitrust theory, and what self-funded employers should be asking their TPA on Monday morning. The bellwether trial isn't until December 7, 2027 — three years of fees away.

About 42% of what the algorithm calls "savings" never makes it to the plan. That's not a doctors-vs-insurers story. It's a third-character story.

▶ Watch the video version: https://youtu.be/H3TQUxJt2Xo 📝 Read the written deep dive (full fee math, sources, 3-question employer checklist): https://danmccoymd.substack.com/p/nobody-in-the-multiplan-lawsuit-is

SOURCES MENTIONED

• AMA on the litigation: https://www.ama-assn.org/health-care-advocacy/judicial-advocacy/health-insurance-price-fixing-real-and-ama-fighting-it
• TMA press release: https://www.texmed.org/Template.aspx?id=67699
• DOJ Statement of Interest coverage: https://www.jdsupra.com/legalnews/doj-adopts-aggressive-stance-against-4076897/
• NYT investigation summary: https://whatleykallas.com/nyt-investigation-shows-how-health-insurers-use-multiplan-to-reduce-payments-to-medical-providers-to-iincrease-their-fees-and-profits-at-the-expense-of-patients/
• Capitol Forum on MultiPlan billing incentives: https://thecapitolforum.com/provider-shows-how-multiplan-incentivizes-him-to-raise-his-billing-rate-multiplan-says-it-does-not-encourage-providers-to-overcharge/
• Seattle Times reprint: https://www.seattletimes.com/nation-world/insurers-reap-hidden-fees-by-slashing-payments-you-may-get-the-bill/
• KFF on 2026 small group premiums: https://www.kff.org/health-costs/how-much-and-why-premiums-are-going-up-for-small-businesses-in-2026/
• Medscape Physician Compensation Report 2025: https://www.medscape.com/slideshow/2025-compensation-overview-6018103

LEGAL DISCLAIMER This episode covers public reporting and pending litigation. All allegations are unproven and may ultimately be rejected in court. MultiPlan, Claritev, and the named insurers deny wrongdoing. Nothing here is legal, financial, or medical advice.

Full sources and the deep dive: danmccoymd.substack.com

49% of plan sponsors reported claims exceeding $1 million last year — double the rate from the year before. And stop-loss carriers are responding not by covering you better, but by finding creative ways to limit their exposure to the most expensive treatments.

In this episode, I break down:

→ Why stop-loss insurance was built for a different era (when catastrophic meant $300K, not $4.25 million)

→ What carriers are actually doing — lasering, exclusions, and reimbursement term misalignment — to push risk back to employers

→ The gene therapy pipeline problem: 48 approved therapies today, dozens more coming, and no historical data to predict frequency

→ Why even jumbo employers who've never needed stop-loss should reconsider

→ The 5 things every self-funded employer needs to do at renewal — including the one question that will tell you everything about your coverage

The mainstream story is that gene therapy is a miracle of modern medicine. It is. But the financial infrastructure wasn't built for this reality, and carriers have decided that the most expensive thing in healthcare is now predictable enough to exclude.

You should find that arrangement concerning.

📺 Watch the full video breakdown:
https://youtu.be/1wwrtwmYAPE

📖 Read the Substack post with sources:
https://open.substack.com/pub/danmccoymd/p/the-stop-loss-crisis-what-self-funded

📧 Subscribe for more healthcare benefits analysis:
https://danmccoymd.substack.com

Andrej Karpathy just released AutoResearch — a 630-line Python tool that lets AI agents run hundreds of experiments overnight on a 35-cent GPU rental. In one test, 35 autonomous agents completed 333 experiments while everyone slept and found 20 improvements that worked. No humans involved.

Meanwhile, your benefits broker spends maybe 20 hours on your entire annual renewal — most of it pulling quotes and formatting spreadsheets — to manage a budget that consumes 25-40% of your total payroll.

In this episode I break down what autonomous research actually is, why the analytical pattern applies directly to healthcare data and benefits design, and three specific questions every employer should be asking their broker at renewal. I also cover the three failure modes of AI research identified by economist Joshua Gans and how Karpathy's system addresses each one.

The benefits consulting industry is about to have its spreadsheet moment. The tools exist, the data exists, the pattern is proven. The only question is whether you'll be the one using it or the one disrupted by someone who does.

Full sources and the deep dive: danmccoymd.substack.com

Also checkout my YouTube Channel.

The AI labs are selling you $10,000 a month in computing power for $600. They're doing it at massive losses. And they have very specific reasons you should understand.

In this episode, I break down the $670B subsidy era fueling healthcare AI — what it means for builders, when it ends, and four strategies to exploit it before the economics correct themselves.

We cover:

• Why AI pricing follows the exact same playbook as early AWS
• The real numbers behind OpenAI's and Anthropic's losses
• Four strategies to maximize subsidized compute (from $600/mo subscriptions to $2,500 local hardware)
• Healthcare startups building real businesses on below-cost AI
• The subsidy timeline: when prices normalize and what to do before they do

Whether you're a healthcare founder, an operator evaluating AI tools, or just trying to understand why trillion-dollar companies are giving away compute — this one lays it out with data, not hype.

Watch on YouTube: https://youtu.be/uDB_VJAX05g

Full sources and the deep-dive subsidy timeline analysis: https://open.substack.com/pub/danmccoymd/p/the-golden-age-of-healthcare-ai-and?r=11z0su&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

Amazon launched an AI health agent inside the Amazon Shopping app — the same app where you order paper towels. It books appointments, manages prescriptions, explains lab results, and connects you to real doctors. Prime members get five free virtual care visits covering 30+ conditions.

This isn't a chatbot experiment. Amazon built this on Bedrock using a multi-agent architecture with auditor and sentinel agents that escalate to human providers in real time. Combined with One Medical's 200+ clinics, Amazon Pharmacy, specialty referral partnerships with Rush and Cleveland Clinic, and a billing relationship with 200 million households — Amazon now owns the full healthcare stack.

In this episode, I break down how Amazon assembled this over nearly a decade (PillPack in 2018, One Medical for $3.9B in 2023), why the pricing strategy matters more than the AI, and the three things every health system executive should be watching over the next 12 months: the employer channel play, the data advantage, and the behavioral shift that happens when asking a healthcare question becomes as casual as checking the weather.

Watch the full video: https://youtu.be/OhHrxHEnSA0?si=B6MeSTiQTGId8388

Full sources and deep dive: https://open.substack.com/pub/danmccoymd/p/amazon-just-put-a-doctor-in-your